About Us

4

Meet The Team

Nuevocor’s LMNA gene therapy is based on decades of research into fundamental mechanisms underlying LMNA-associated disease enabled by the development of novel technologies on the part of scientific co-founders Colin Stewart and Brian Burke. Together with the AAV gene therapy and cardiac disease modeling expertise of scientific co-founders Mark Kay and Jianming Jiang respectively, Nuevocor is well-positioned to cure LMNA and other genetic cardiomyopathies, amongst other cardiac diseases. 

YC1_1_edited.jpg

Yann Chong Tan, PhD

Founding CEO

Extensive experience in the biotech space, successful inventor and entrepreneur who co-founded a Nasdaq-listed biotech, Atreca.

Managing Director, EVX Ventures

WhatsApp Image 2021-06-03 at 10.04.52 AM

Euan Ashley, MD, PhD

Scientific Advisory Board Member

Leading medical geneticist and cardiologist at Stanford University.
Co-founder of Personalis and other companies.

Professor of Medicine and Genetics at Stanford University  

WhatsApp Image 2021-05-25 at 10.40.54 AM

Brian Burke, PhD

Scientific Co-Founder

Distinguished cell biologist in the area of the nuclear envelope, including lamins and the LINC complex, through the innovative use of microscopic and biochemical technologies.

Research Director at the Agency for Science, Technology and Research, Singapore

Mia Hu.jpg

Mia Hu, PhD

Board Member

Healthcare investor and incubator with extensive research experience in regenerative medicine.

Associate Director of Boehringer Ingelheim Venture Fund

WhatsApp%20Image%202021-05-25%20at%203.5

Jianming Jiang, PhD

Scientific Co-Founder

Emerging leader in investigating the regulatory mechanisms underlying cardiovascular disease through the use of AAV vectors and other cutting-edge technologies.

Asst. Prof. in Biochemistry at the National University of Singapore

WhatsApp%20Image%202021-06-03%20at%207.0

Mark Kay, MD, PhD

Scientific Co-Founder

World expert in the area of gene therapy technologies for the treatment of genetic and acquired diseases, including the discovery of novel adeno-associated virus (AAV) capsids.

Head of the Division of Human Gene Therapy; and Professor of Pediatrics and Genetics at Stanford University

WhatsApp%20Image%202021-06-03%20at%2011.

Cheryl Lee

Associate Director,
Project Management

Accumulated experience in research project and funding management as administrative and operations lead for both research grantees and grant funder in the Singapore public sector.

WhatsApp Image 2021-05-31 at 3.52.30 PM.

Yin Loon Lee, PhD

Co-Founder and Senior Director, Biology

As a postdoctoral fellow with Brian Burke, investigated mechanism of disease in laminopathies, and contributed to development of Nuevocor's technology.

WhatsApp Image 2021-05-31 at 3.52.00 PM.

XQ Lin

Board Member

Seasoned Innovator, Entrepreneur,

and Investor.

Chairman EVX Ventures &
Carmine Therapeutics; CEO Esco Lifesciences

WhatsApp Image 2021-07-29 at 2.40.36 PM.jpeg

David Russell

Senior Advisor

Expert on viral gene therapy and biology, and genetic manipulation of stem cells. Founded and sold Universal Cells, a biotech company built on technologies developed in his academic lab.

Professor Emeritus of Medicine at University of Washington

WhatsApp Image 2021-06-03 at 10.33.56 AM

Idina Shi, PhD

Associate Director, Operations and Business Development

Combined business development and corporate strategy experience through tenures as biotechnology portfolio manager and science policy official in Singapore government science agency.

WhatsApp Image 2021-05-25 at 11.10.03 AM

Colin Stewart, PhD

Scientific Co-Founder

Pioneer in techniques underpinning mouse experimental genetics, and developer of multiple mouse models for laminopathies for elucidating mechanisms of disease.

Research Director at the Agency for Science, Technology and Research, Singapore

WhatsApp Image 2021-05-31 at 3.51.45 PM.

Hendrikje Werner, PhD

Principal Scientist

As a postdoctoral fellow with Colin Stewart, played pre-eminent roles in studies that resulted in Nuevocor’s lead program as well as its target discovery platform.

WhatsApp Image 2021-05-31 at 3.53.22 PM.

Weiyi Zhang, PhD

Board Member

Pharma veteran with a wealth of industry experience in drug discovery and innovation.

Former Managing Director of Boehringer Ingelheim Venture Fund China

CEO of RiboX Therapeutics  

Careers

Please visit Nuevocor’s LinkedIn page to view our job listings by clicking here.

When you're ready, please click: